Latest News
2017 Annual SMA Conference Booklet Now Posted
The 2017 Annual SMA Conference Booklet is now posted. The booklet includes: A complete schedule with information about the special events we’ve got planned including: the Family Friendly Research Poster […]
SMA Newborn Screening Moves Forward in Missouri and Florida
The spinal muscular atrophy community is celebrating significant progress toward adding SMA to newborn screening panels in two states. Missouri to Become the First State to Screen for SMA In […]
AveXis Announces Alignment with the FDA on Company’s GMP Commercial Manufacturing Process for AVXS-101
AveXis today announced alignment with the U.S. Food and Drug Administration (FDA) on the company’s Good Manufacturing Practice (GMP) commercial manufacturing process for AVXS-101 following the receipt of minutes from […]
Update: President’s Budget Proposes Significant Cuts to Federal Health Programs That Are Critically Important to SMA Patients and Families
The President recently released his detailed budget proposal for Fiscal Year 2018, which proposed significant funding cuts to numerous federal programs, including many that have a direct impact on the […]
Anthem Updates Insurance Policy for Spinraza
Anthem Inc. recently announced an updated insurance policy for the use of Spinraza (nusinersen) for treatment of spinal muscular atrophy. The revised policy expands criteria for treatment to onset of […]
European Commission Grants Marketing Authorization for Spinraza, Making it First Approved SMA Treatment in the European Union
Biogen announced today that the European Commission (EC) has granted a marketing authorization for Spinraza for the treatment of spinal muscular atrophy (SMA), making it the first approved treatment in […]